Wiskott-Aldrich syndrome (WAS) is characterized by primary immunodeficiency, thrombocytopenia and eczema. Patients with WAS have an increased risk to develop tumors. Non-Hodgkin lymphoma (NHL) represents the most common malignancy occurring in WAS-affected patients, diffuse-large-B-cell lymphoma is the most frequently encountered variant. We describe a case of a patient with WAS and NHL in the pharynx, an atypical tumor site presentation. The patient was successfully treated with a reduced dose chemotherapy regimen plus anti-CD20 monoclonal antibody. He is in complete remission 3 years from the start of treatment. Pediatr Blood Cancer 2012;59:318-319. © 2011 Wiley Periodicals, Inc.
Coccia, P., Mastrangelo, S., Ruggiero, A., Scalzone, M., Rosolen, A., Maurizi, P., Riccardi, R., Treatment of pharyngeal non-Hodgkin lymphoma in a patient with Wiskott-Aldrich syndrome, <<PEDIATRIC BLOOD & CANCER>>, 2012; 59 (2): 318-319. [doi:10.1002/pbc.23393] [http://hdl.handle.net/10807/23225]
Treatment of pharyngeal non-Hodgkin lymphoma in a patient with Wiskott-Aldrich syndrome
Coccia, Paola;Mastrangelo, Stefano;Ruggiero, Antonio;Scalzone, Maria;Maurizi, Palma;Riccardi, Riccardo
2012
Abstract
Wiskott-Aldrich syndrome (WAS) is characterized by primary immunodeficiency, thrombocytopenia and eczema. Patients with WAS have an increased risk to develop tumors. Non-Hodgkin lymphoma (NHL) represents the most common malignancy occurring in WAS-affected patients, diffuse-large-B-cell lymphoma is the most frequently encountered variant. We describe a case of a patient with WAS and NHL in the pharynx, an atypical tumor site presentation. The patient was successfully treated with a reduced dose chemotherapy regimen plus anti-CD20 monoclonal antibody. He is in complete remission 3 years from the start of treatment. Pediatr Blood Cancer 2012;59:318-319. © 2011 Wiley Periodicals, Inc.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
